173 related articles for article (PubMed ID: 15206060)
1. The pharmacogenetics of antiretroviral therapy: a review of studies to date.
Quirk E; McLeod H; Powderly W
Clin Infect Dis; 2004 Jul; 39(1):98-106. PubMed ID: 15206060
[TBL] [Abstract][Full Text] [Related]
2. The clinical implications of antiretroviral pharmacogenomics.
Fox J; Boffito M; Winston A
Pharmacogenomics; 2006 Jun; 7(4):587-96. PubMed ID: 16753006
[TBL] [Abstract][Full Text] [Related]
3. Individualising HIV treatment--pharmacogenetics and immunogenetics.
Telenti A; Aubert V; Spertini F
Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
[No Abstract] [Full Text] [Related]
4. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
Phillips EJ; Mallal SA
Curr Opin Infect Dis; 2008 Feb; 21(1):16-24. PubMed ID: 18192781
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of antiretrovirals.
Tozzi V
Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
[TBL] [Abstract][Full Text] [Related]
8. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
9. Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
Hu K; Xiang Q; Wang Z; Mu GY; Zhang Z; Ma LY; Xie QF; Chen SQ; Zhou S; Zhang XD; Cui YM
BMC Infect Dis; 2019 Jul; 19(1):583. PubMed ID: 31277607
[TBL] [Abstract][Full Text] [Related]
10. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
[TBL] [Abstract][Full Text] [Related]
11. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
Cressey TR; Lallemant M
Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
[TBL] [Abstract][Full Text] [Related]
13. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
[TBL] [Abstract][Full Text] [Related]
15. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
Cholewińska G
Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
[TBL] [Abstract][Full Text] [Related]
16. Scientists find some genes a bad omen for anti-HIV drug.
Stephenson J
JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
[No Abstract] [Full Text] [Related]
17. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of adverse effects due to antiretroviral drugs.
Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
Nolan D; Gaudieri S; Mallal S
J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
[TBL] [Abstract][Full Text] [Related]
20. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
